Compare BEEM & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | JSPR |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 26.3M |
| IPO Year | 2018 | 2019 |
| Metric | BEEM | JSPR |
|---|---|---|
| Price | $1.41 | $0.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $3.50 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.5M | 672.8K |
| Earning Date | 04-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.77 | 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,236,000.00 | N/A |
| Revenue This Year | $40.48 | N/A |
| Revenue Next Year | $32.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $0.32 |
| 52 Week High | $4.04 | $2.69 |
| Indicator | BEEM | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 48.45 |
| Support Level | $1.38 | $0.64 |
| Resistance Level | $1.42 | $1.01 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 23.91 | 51.20 |
Beam Global is a clean-technology innovation company. It develop, design, engineer, manufacture, and sell high-quality, renewably energized infrastructure products for electric vehicle ( EV ) charging, infrastructure for Smart Cities (the interconnected physical and digital elements within a city that utilize technology to enhance efficiency, sustainability, and quality of life for residents), energy security and disaster preparedness and energy-dense battery solutions in safe, compact and form-factors. Additionally, the company manufactures structures with electronic integration such as streetlighting, cell towers and energy infrastructure products as well as power electronics including invertors, charge controllers, power supplies and LED lighting.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.